Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Quince Therapeutics Inc (QNCX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Quince Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.060 +0.030    +2.91%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.000
-0.060
-5.660%
18:08:54 - Real-time Data
  • Volume: 119,395
  • Bid/Ask: 1.000 / 1.130
  • Day's Range: 0.999 - 1.080
Type:  Equity
Market:  United States
Quince Therapeutics 1.060 +0.030 +2.91%

Quince Therapeutics Inc Company Profile

 
Get an in-depth profile of Quince Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

32

Equity Type

ORD

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Contact Information

Address 611 Gateway Boulevard Suite 273
South San Francisco, 94080
United States
Phone 415-910-5717
Fax -

Top Executives

Name Age Since Title
Marwan Sabbagh - - Member of Clinical Advisory Board
Ted Yednock 66 - Member of Scientific Advisory Board
Clive Holmes - 2020 Clinical Advisory Board Member
Margaret A. McLoughlin 61 2015 Independent Director
Mathew Bogyo - - Member of Scientific Advisory Board
Una S. Ryan 82 2019 Lead Independent Director
Jeffrey L. Cummings 74 2019 Member of Clinical Advisory Board
Eric M. Gordon - - Member of Scientific Advisory Board
Jan Potempa - - Member of Scientific Advisory Board
David Munoz - - Member of Clinical Advisory Board
Ilan Zipkin - - Member of Scientific Advisory Board
Mark Ryder - - Member of Clinical Advisory Board
Merce Boada - 2020 Member of Clinical Advisory Board
Martin Rhys Farlow - - Member of Clinical Advisory Board
Mark Brody - - Member of Clinical Advisory Board
Richard C. White - - Member of Scientific Advisory Board
Christopher J. Senner 56 2019 Independent Director
James A. Spudich 82 2024 Member of Scientific Advisory Board
Vladimir R. Muzykantov - 2024 Member of Scientific Advisory Board
Pierre N. Tariot - 2019 Member of Clinical Advisory Board
David A. Lowe 77 - Member of Scientific Advisory Board
David A. Lamond 49 2015 Independent Chairman of the board
Lon S. Schneider - 2019 Member of Clinical Advisory Board
June Bray 69 2022 Independent Director
Thomas P. Laughren - 2019 Clinical Advisory Board Member
Carlo Brugnara - 2024 Member of Scientific Advisory Board
William Jusko - 2024 Member of Scientific Advisory Board
Howard Lederman - 2024 Member of Scientific Advisory Board
Susan Perlman - 2024 Member of Scientific Advisory Board
Mauro Magnani - 2024 Chairman of Scientific Advisory Board
Rajiv Patni 55 2024 Independent Director
Luca Benatti 63 2023 Independent Director
Dirk Thye 54 2022 CEO, Chief Medical Officer & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

QNCX Comments

Write your thoughts about Quince Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email